Dr. Kemp's research focuses on improving psychiatric outcomes by targeting the treatment of comorbid medical conditions, particularly obesity, pre-diabetes, and metabolic syndrome. He is currently investigating whether insulin sensitizers can reduce the severity of depression symptoms by acting on novel pathophysiological targets that influence mood. Dr. Kemp is a recipient of the International Society for Bipolar Disorders Research Fellowship Award and the DBSA Klerman Young Investigator Award. His research is currently supported by NARSAD and the Cleveland Foundation.